RYTELO (imetelstat) is a prescription medicine used to treat a condition called low- to intermediate-1 risk See more
myelodysplastic syndromes (MDS) in adults:
and
It is not known if RYTELO is safe and effective in children.

The REACH4RYTELO Patient Support Program can help patients who have been prescribed RYTELO navigate access and coverage.*
Benefits Investigation: support during the process of determining your insurance benefits for RYTELO and eligibility for affordability programs
Prior Authorization (PA): provide information relevant to navigating the PA approval process from your insurance company
Appeals Support: provide information relevant to navigating appeals of any denied PA requests
*The accurate completion of reimbursement- or coverage-related documentation is the responsibility of the healthcare provider and patient. REACH4RYTELO and its agents make no guarantee regarding coverage and reimbursement for RYTELO.
Once you have been enrolled in REACH4RYTELO and a benefits investigation has been conducted, your doctor will receive a summary of the results of the benefits investigation.* If information is missing, a Case Manager will follow up with your doctor.
Your doctor should respond promptly to a request for further information from a Case Manager to avoid any delays.
For eligible, commercially insured patients, the REACH4RYTELO Copay Program offers savings up to $10,650 per calendar year.† There are no income requirements to participate in the program. Terms and conditions apply.
If eligible, you may pay as little as $0 out-of-pocket for RYTELO, which includes copay and coinsurance, up to $9450 annually.
If eligible, you may save up to $100 per infusion, up to $1200 annually. Itemized explanation of benefits (EOBs) must have separate line for out-of-pocket cost of administration.
†The REACH4RYTELO Copay Program is not available to patients with any form of government insurance (such as Medicaid, Medicare, TRICARE, and VA). Patients must meet certain eligibility criteria to qualify for this program, including requirements related to the diagnosis for which the patient is receiving treatment and the patient’s insurance status. To enroll in the Copay Program, patients must first enroll in REACH4RYTELO. If eligible for the Copay Program, the patient may pay as little as $0 out-of-pocket for RYTELO with a maximum benefit of $9450 per year for the cost of the drug and a maximum benefit of $1200 per year for the cost of administration (up to $100 per infusion). An itemized EOB must be provided with a separate line for the out-of-pocket cost of administration fee. Residents of MA, MI, MN, and RI are not eligible to receive copay assistance for product administration and are therefore only eligible for a maximum benefit of $9450 per year for the cost of the drug. For Copay Program eligibility questions, contact a representative from REACH4RYTELO at 1-844-479-8356.
All programs provided through REACH4RYTELO are subject to eligibility requirements. Geron reserves the right to modify or discontinue REACH4RYTELO at any time without notice.
RYTELO (imetelstat) is a prescription medicine used to treat a condition called low- to intermediate-1 risk myelodysplastic syndromes (MDS) in adults:
and
It is not known if RYTELO is safe and effective in children.
Before you receive RYTELO (imetelstat), tell your healthcare provider about all of your medical conditions, including if you:
Females who are able to become pregnant:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
RYTELO may cause serious side effects, including:
Your healthcare provider will do blood tests to check your platelet and neutrophil counts before starting treatment with RYTELO, weekly for the first 2 cycles of treatment, before you receive each additional cycle, and as needed during your treatment.
Your healthcare provider may delay your next treatment, decrease your dose, or stop treatment with RYTELO if you develop thrombocytopenia or neutropenia during treatment.
RYTELO may cause serious side effects, including:
The most common side effects of RYTELO include:
These are not all of the possible side effects of RYTELO. Call your doctor for more information and medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/MedWatch or call 1-800-FDA-1088.
Please see RYTELO (imetelstat) full Prescribing Information, including Medication Guide.
Before you receive RYTELO (imetelstat), tell your healthcare provider about all of your medical conditions, including if you:
Females who are able to become pregnant:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
RYTELO may cause serious side effects, including:
Your healthcare provider will do blood tests to check your platelet and neutrophil counts before starting treatment with RYTELO, weekly for the first 2 cycles of treatment, before you receive each additional cycle, and as needed during your treatment.
Your healthcare provider may delay your next treatment, decrease your dose, or stop treatment with RYTELO if you develop thrombocytopenia or neutropenia during treatment.
RYTELO may cause serious side effects, including:
The most common side effects of RYTELO include:
These are not all of the possible side effects of RYTELO. Call your doctor for more information and medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/MedWatch or call 1-800-FDA-1088.
Please see RYTELO (imetelstat) full Prescribing Information, including Medication Guide.
RYTELO (imetelstat) is a prescription medicine used to treat a condition called low- to intermediate-1 risk myelodysplastic syndromes (MDS) in adults:
and
It is not known if RYTELO is safe and effective in children.